Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer

Osamu Nishiyama1*, Shigeki Shimizu2, Koji Haratani3, Kosuke Isomoto3, Junko Tanizaki3, Hidetoshi Hayashi3, Ryo Yamazaki1, Takashi Oomori1, Yusaku Nishikawa1, Akiko Sano1, Kazuhiko Nakagawa3 and Yuji Tohda1

Abstract

Background: The utility of bronchoscopy for patients with suspected immune checkpoint inhibitor (ICI)-related pneumonitis is currently debatable. The purpose of this study was to examine the findings of bronchoalveolar lavage (BAL) analysis and transbronchial lung biopsy (TBLB) in non-small cell lung cancer (NSCLC) patients with ICI-related pneumonitis, and to elucidate the clinical significance of bronchoscopy for this health condition.

Patients and methods: Consecutive NSCLC patients treated with ICIs, diagnosed with ICI-related pneumonitis after undergoing bronchoscopy between October 2015 and March 2019 were retrospectively screened. Findings of BAL fluid analysis and/or TBLB specimen histology were reviewed.

Results: Twelve patients underwent bronchoscopy for the diagnosis of ICI-related pneumonitis, ten of whom underwent BAL. An increase in the proportion of lymphocytes higher than 20% was observed in all ten patients. An increase in the proportion of neutrophils (> 10%) and eosinophils (> 10%) was observed in two and one patient, respectively. TBLB specimens were analyzed for eight patients. Major histologic findings included alveolitis in seven (87.5%) and organizing pneumonia (OP) in five (62.5%) patients. Other findings included acute lung injury and fibrosis. All twelve patients demonstrated favorable outcomes.

Conclusion: A major characteristic of BAL analysis in ICI-related pneumonitis with NSCLC was an increased proportion of lymphocytes. The histologic features of lung tissue included alveolitis and/or OP. Acute lung injury and fibrosis were observed. Although the necessity of bronchoscopy should be determined on a case-by-case basis, it is necessary to assess these parameters when proper differential diagnosis is needed.

Keywords: Alveolitis, Bronchoalveolar lavage, Lung biopsy, Lymphocyte, Organizing pneumonia

Introduction

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many types of cancer. Over the past few years, indications for the use of ICIs have expanded significantly. Although the survival of cancer patients treated with such agents was prolonged, the risk of immune-related adverse events (irAEs), such as dermatitis, colitis, endocrinopathy, hepatotoxicity,
neuropathy, and pneumonitis, was increased [1–3]. ICI-related pneumonitis is one of the most common causes of ICI-related deaths [4–6].

In patients with non-small cell lung cancer (NSCLC) who received ICI monotherapy, the incidence of ICI-related pneumonitis for all grades was reported to range from 1 to 12% [7]. Recent meta-analyses reported that the overall incidence of ICI-related pneumonitis is 4.5% [8]. As for severe pneumonitis, the incidence is reportedly 0.8% to 1.5% for grade 3 or higher, and 0.4% for grade 5 [7, 8].

The diagnosis of ICI-related pneumonitis is usually carried out based on clinical signs, including symptomatology, time to onset, and radiological patterns on high-resolution computed tomography (HRCT). Radiographic patterns that are typical of ICI-related pneumonitis include organizing pneumonia (OP), non-specific interstitial pneumonia (NSIP), hypersensitivity pneumonia (HP), diffuse alveolar damage (DAD), acute interstitial pneumonia (AIP), diffuse alveolar damage syndrome, ground-glass opacity, and non-specific patterns [4, 5, 9]. Diagnosis is straightforward when the clinical picture is consistent with ICI-related pneumonitis. However, it is sometimes difficult when other possible etiologies, such as lymphangitic spread of tumor, infection, alveolar hemorrhage, and acute exacerbation of existing interstitial lung disease are present.

The utility of bronchoscopy for patients with suspected ICI-related pneumonitis is currently debatable. Although some practice guidelines recommend bronchoalveolar lavage (BAL) and/or transbronchial lung biopsy (TBLB) for suspected ICI-related pneumonitis cases of grade 2 and above [1–3], these processes are not generally performed in clinical practice.

The purpose of this study was to examine the findings of BAL and/or TBLB in NSCLC patients with ICI-related pneumonitis, and to elucidate the clinical significance of bronchoscopy in such patients.

**Methods**

**Patients**

Consecutive patients with NSCLC who had been treated with ICIs at our university hospital, and who had been diagnosed with ICI-related pneumonitis after undergoing bronchoscopy between October 2015 and March 2019 were retrospectively screened. The findings of BAL analysis and/or histology of TBLB specimens were reviewed.

Chest HRCT findings obtained prior to bronchoscopy were also reviewed. Patterns of the HRCT findings were determined according to the classification proposed previously [4, 5, 9].

**BAL and TBLB**

Bronchoscopy was performed based on the physician’s decision because formal clinical indications have not been established. However, it was encouraged for all patients with suspected ICI-related pneumonitis during the study period. BAL was performed with four (50 mL each) aliquots of sterile saline solution, followed by manual aspiration using a bronchoscope [10]. The aspirates of four consecutive aliquots were pooled, and centrifuged to separate the fluid from the cells. Cell differentials were obtained by manual enumeration on cytospin preparations using a Diff-QuikTM stain (Scientific Products, McGraw Park, IL). Cell surface markers were examined using fluorescein isothiocyanate-conjugated CD4 and CD8 monoclonal antibodies (Ortho Diagnostics Inc., Raritan, NJ, USA) by flow cytometry.

TBLB specimens were obtained mainly from the lobes in which lung abnormalities were observed. The histological findings were reviewed by a pathologist (S.S.) who specializes in interstitial lung diseases.

**Treatment and response**

Treatments performed for ICI-related pneumonitis were reviewed. Treatment responses were also evaluated.

**Statistical analysis**

Continuous variables are summarized as mean ± standard deviation (SD), and categorical variables by the actual numbers. Analyses were performed with Statflex ver.7 (Artec Co., Ltd., Osaka, Japan).

**Results**

One hundred and forty consecutive patients with NSCLC were treated with ICIs during the study period. Of these, 22 patients were suspected to have ICI-related pneumonitis, and 12 of them underwent bronchoscopy for diagnosis (Fig. 1). Patients who underwent bronchoscopy were admitted to our hospital before the procedure. Subsequently, all 12 patients were clinically...
diagnosed with ICI-related pneumonitis, and other etiologies were excluded.

Patient characteristics at admission are shown in Table 1. The mean age was 68.8 ± 6.9 years, for nine men and three women. Among the patients, eight had adenocarcinoma, three had squamous cell carcinoma, and one had NSCLC that was not specific. Pre-admission ICI treatment included nivolumab and pembrolizumab for seven and five patients, respectively. The ICIs were used as a single-agent regimen. Duration of ICI use before the diagnosis of ICI-related pneumonitis was 5.0 ± 4.1 month. All patients complained of dyspnea of modified Medical Research Council (mMRC) grade 1 to 4, except three who had no dyspnea. The grade of pneumonitis was 1 in two, 2 in seven, and 3 in three patients; none of the patients had grade 4 pneumonitis.

The findings of BAL analysis are presented in Table 2. BAL was performed in ten of the twelve patients who underwent bronchoscopy. Comparing with upper limits of normal for nonsmokers that were proposed by the American Thoracic Society practice guideline (lymphocytes: 15%, neutrophils: 3%, eosinophils: 1%) [10], the proportions of lymphocytes, neutrophils, and eosinophils were increased by 33.5 ± 24.6%, 1.3 ± 5.7%, 2.5 ± 5.6% above the upper limit. In all ten patients the proportion of lymphocytes increased > 20%. The proportion of neutrophils was found to be > 10% in two patients, whereas > 10% in the proportion of eosinophils was observed in one patient.

The radiographic patterns in chest HRCT, and the major histological findings of the TBLB specimens are shown in Table 3. Chest HRCT of the twelve patients revealed OP, HP, and NSIP patterns in eight (66.6%), three (25.0%), and one (8.3%) patients, respectively. TBLB specimens were obtained from eight patients. The main histologic findings included alveolitis (mild and moderate thickening of alveolar septa by the infiltration of lymphocytes and plasma cells) and OP (airspace filling by fibroblast plugs). Alveolitis was observed in seven (87.5%), and OP was observed in five (62.5%) out of eight patients whose lung specimens could be obtained; co-occurrence of alveolitis and OP was observed in four (50.0%) patients. Other findings included acute lung injury and fibrosis, which were observed in different patients.

Cases with demonstrative findings of chest radiography, chest HRCT, and TBLB histology are shown in Figs. 2 and 3. Radiographic findings of OP pattern, and

**Table 1** Characteristics of the selected patients at admission (n=12)

| Variables              | Values                  |
|------------------------|-------------------------|
| Age, yrs               | 68.8 ± 6.9              |
| Gender, male/female    | 9/3                     |
| Types of NSCLC, adeno/squamous/NOS | 8/3/1                  |
| Types of ICI, nivolumab/pembrolizumab | 7/5                  |
| Duration of ICI use, mo| 5.0 ± 4.1               |
| mMRC dyspnea grade, 0/1/2/3/4 | 3/2/5/1/1            |
| Grade of pneumonitis, 1/2/3/4 | 2/7/3/0               |

Values are expressed as mean ± standard deviation or by the actual number. Grade of pneumonitis was assessed according to CTCAE v5.0.

CTCAE, Common Terminology Criteria for Adverse Events; ICI, immune checkpoint inhibitor; mMRC, modified Medical Research Council; NSCLC, non-small cell lung cancer; NOS, not otherwise specified

**Table 2** Findings of bronchoalveolar lavage analysis

| Case | Age | Gender | Smoking status | Site               | Recovery rate (%) | TCC (× 10⁵/mL) | AM (%)   | Lym (%)   | Neu (%)   | Eos (%)   | CD4:CD8 |
|------|-----|--------|----------------|--------------------|-------------------|-----------------|----------|-----------|-----------|-----------|----------|
| 1    | 68  | M      | Former         | –                  | –                 | –               | –        | –         | –         | –         | –        |
| 2    | 73  | F      | Never          | rt. B¹             | 49.0              | 2.1             | 52.6     | 44.8      | 1.8       | 0.8       | 1.5      |
| 3    | 68  | M      | Former         | rt. middle lobe    | 59.5              | 1.6             | 47.0     | 46.4      | 5.8       | 0.8       | 0.3      |
| 4    | 66  | M      | Former         | lt. B²             | 58.0              | 2.7             | 56.4     | 53.5      | 2.2       | 0.9       | 0.3      |
| 5    | 51  | M      | Current        | rt. B³             | 59.0              | 2.2             | 5.8      | 90.4      | 0.8       | 3.0       | 0.5      |
| 6    | 79  | M      | Former         | lt. B¹             | 49.0              | 1.3             | 12.2     | 86.0      | 1.4       | 3.0       | 0.5      |
| 7    | 70  | M      | Former         | lt. B¹             | 43.5              | 2.5             | 20.4     | 76.6      | 1.4       | 1.6       | 3.6      |
| 8    | 74  | M      | Former         | rt. B¹             | 17.5              | 0.4             | 32.2     | 47.8      | 15.6      | 4.4       | 0.5      |
| 9    | 72  | M      | Former         | –                  | –                 | –               | –        | –         | –         | –         | –        |
| 10   | 71  | M      | Former         | rt. B¹             | 57.0              | 3.5             | 54.0     | 30.0      | 14.0      | 2.0       | 0.1      |
| 11   | 63  | F      | Never          | rt. B¹             | 70.2              | 2.3             | 16.2     | 64.2      | 0.4       | 19.2      | 0.5      |
| 12   | 70  | F      | Never          | rt. B¹             | 41.5              | 1.2             | 77.8     | 20.4      | 0.4       | 0.4       | 0.5      |

Cases 1–5, 7, 8, 12: adenocarcinoma; Cases 6, 9, 11: squamous cell carcinoma; Case 10: not otherwise specified

AM, alveolar macrophage; CD, cluster of differentiation; Eos, eosinophils; Lym, lymphocytes; Neu, neutrophils; TCC, total cell count
The ten patients who did not undergo bronchoscopy consisted of seven with adenocarcinoma, two with squamous cell carcinoma, and one with NSCLC that was non-specific. The mean age of the ten patients was 64.8 ±15.8 years, which included six men and four women. ICI treatment at admission included nivolumab and pembrolizumab for seven and three patients, respectively; the ICIs were used as a single-agent regimen. The grade of pneumonitis at admission was 1 in three patients, 2 in four, 3 in one, and 4 in two patients. Corticosteroid treatment for ICI-related pneumonitis was provided to nine of the ten patients, whereas one did not receive any treatment. Abnormal shadows on chest HRCTs due to ICI-related pneumonitis improved or disappeared in eight patients. However, two patients died of respiratory failure 3 and 31 days after admission, respectively, despite high-dose corticosteroid therapy; both patients suffered from grade 4 pneumonitis at admission.

### Discussion

In this study, we examined the findings of BAL and/or TBLB in twelve consecutive NSCLC patients with ICI-related pneumonitis. Analysis of BAL indicated of >20% in the proportion of lymphocytes in all patients who underwent BAL examination. The main histologic features in lung tissue revealed by TBLB included alveolitis and OP. Acute lung injury and fibrosis were also observed. All patients who were treated with corticosteroids and/or infliximab showed favorable responses to the treatments; one patient improved without therapy.

ICIs are one of the most important drugs for treating patients with advanced or recurrent NSCLC. Cytotoxic T-lymphocyte-associated protein 4 and programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) are the most relevant targets for immunotherapy [11]. For patients with NSCLC, ICIs directed at PD-1 (nivolumab and pembrolizumab) were approved first for clinical use in Japan. This was followed by the approval of ICIs directed at PD-L1 (atezolizumab and durvalumab). These ICIs are currently used in clinical practice according to established evidence for each ICI, for example, as first-line treatment, second-line or later treatments, and in combination with cytotoxic chemotherapy [12]. However, as the opportunities for using ICIs increase, the frequency of irAEs is also increasing. In irAEs, pneumonitis is considered important because it can be lethal [4–6].

The pathophysiology of ICI-related pneumonitis is poorly understood. Although some practice guidelines recommend BAL and/or TBLB for suspected ICI-related pneumonitis of grade 2 or higher [1–3], it seems that many patients with clinically suspected ICI-related pneumonitis disappeared in six patients, and improved in the other six after the treatments (Table 4).
pneumonitis never undergo bronchoscopy in clinical practice. Although several case presentations have been reported in which findings of BAL and/or TBLB were available, only a few reported the findings in a case series [6, 13]. To our knowledge, the present study is the first to systemically detail BAL and histological findings, and correlate these findings with radiographic findings in NSCLC patients with ICI-related pneumonitis. Notably, pathologic OP was observed not only in patients with radiographic OP patterns, but also in those with HP and NSIP patterns. Pathologic findings suggestive of acute lung injury were observed in patients with radiological OP patterns. The present study suggests that alveolitis and OP are major pathologic findings of lung specimens for patients with ICI-related pneumonitis, which do not necessarily correspond to radiologic patterns.

A previous study demonstrated that the proportion of lymphocytes of >15% in BAL fluid was observed in 24 out of 30 (80%) patients with ICI-related pneumonitis whose BAL findings could be evaluated, although patients with lung cancer as well as melanoma and others were included [6]. These results were similar to ours. Another study on lung tissues of patients with different types of cancer and ICI-related pneumonitis revealed OP to be a major pathologic finding in seven out of nine (77.8%) patients [13]. Diffuse alveolar damage and acute fibrinous pneumonitis were also observed in one patient each. These findings are also similar to our results. However, it is noteworthy that pathologic findings suggestive of acute lung injury were also seen in a patient in whom the proportion of lymphocytes in BAL fluid increased in the present study. It should be noted that the term acute lung injury pattern is sometimes used by pathologists when

Fig. 2 Chest X-ray image showing bilateral lung infiltrates and ground-glass opacities (A). High-resolution computed tomography image of chest image showing bilateral pulmonary ground-glass opacities and focal consolidations, suggestive of organizing pneumonia (OP) pattern (B). Transbronchial lung biopsy specimen of right S4 shows alveolitis (C Hematoxylin and Eosin) and intraluminal OP (arrow) (D Elastica van Gieson). (Case No.1)
Fig. 3 Chest X-ray image showing lung infiltrates in right upper and left middle lung (A). High-resolution computed tomography image of chest image showing pulmonary ground-glass opacities in the left upper and lower lobes (B). Consolidation is also seen in the right upper lobe, suggestive of organizing pneumonia (OP) pattern. Transbronchial lung biopsy specimen of left S8 shows edema and fibroblast proliferation in alveolar walls, alveolitis (C Hematoxylin and Eosin), fibrinous exudate (arrow) in alveolar spaces, and enlarged type 2 pneumocytes (D Hematoxylin and Eosin). No hyaline membrane is seen in the specimen. (Case No. 4)

Table 4 Treatment approach for ICI-related pneumonitis and reactivity for chest HRCT findings

| Case | Initial treatment                                    | Chest HRCT findings |
|------|------------------------------------------------------|---------------------|
| 1    | 0.5 mg/kg prednisolone (p.o.)                        | Disappeared         |
| 2    | 1 mg/kg prednisolone (p.o.)                          | Disappeared         |
| 3    | 0.5 g methylprednisolone (i.v.) x 3 days followed by 1 mg/kg prednisolone (p.o.) | Markedly improved |
| 4    | 3 mg/kg infliximab (i.v.)                            | Markedly improved   |
| 5    | 1 mg/kg prednisolone (p.o.)                          | Markedly improved   |
| 6    | 0.5 mg/kg prednisolone (p.o.)                        | Markedly improved   |
| 7    | 1 mg/kg prednisolone (p.o.) and 3 mg/kg infliximab (i.v.) | Disappeared |
| 8    | 1 mg/kg prednisolone (p.o.)                          | Markedly improved   |
| 9    | 1 mg/kg prednisolone (p.o.)                          | Markedly improved   |
| 10   | 1 mg/kg prednisolone (p.o.)                          | Disappeared         |
| 11   | 1 mg/kg prednisolone (p.o.)                          | Disappeared         |
| 12   | none                                                 | Disappeared         |

Daily dose is as shown for prednisolone and methylprednisolone. The dose of prednisolone was gradually decreased in all patients who underwent corticosteroid treatment. Infliximab was administered with a single dose of 3 mg/kg.

HRCT, high-resolution computed tomography; ICI, immune checkpoint inhibitor; i.v., intravenous; p.o., per os (oral administration)
both diffuse alveolar damage and OP are present in the same biopsy, or if the findings cannot be easily pigeonholed into either category [14]. Our case with pathologic findings suggestive of acute lung injury was presumably corresponded to this pattern.

Considering the responses to treatments for ICI-related pneumonitis, all patients who underwent bronchoscopy showed favorable clinical courses in the present study. Given that patients with cryptogenic OP of idiopathic interstitial pneumonia usually have a good response to corticosteroids [15], the observation is quite reasonable. None of the patients, including the one whose lung specimen showed pathological findings suggestive of acute lung injury, died of ICI-related pneumonitis. This suggests that the increased proportion of lymphocytes in BAL fluid can be a marker for favorable treatment response, even in patients with lungs showing acute lung injury. Pathological findings of acute lung injury are usually considered refractory to treatment, and have a poor prognosis. This is presumed from the knowledge of idiopathic interstitial pneumonia [15], as well as from the experience of the induction of lung disease by cytotoxic drugs, such as amiodarone, bleomycin, and epidermal growth factor receptor-tyrosine kinase inhibitor. Furthermore, an increased proportion of neutrophils in BAL fluid is usually recognized as a marker of poor prognosis. In the present study, two patients showed increased neutrophil counts in BAL fluid, which was accompanied by an increased lymphocyte count. No patient showed increased neutrophil count in BAL fluid as a major finding.

If bronchoscopy could be performed in patients who died of ICI-related pneumonitis, different findings in the BAL analysis might have been obtained. Given that an increased proportion of neutrophils in BAL fluid was reported in patients with AIP and acute exacerbation of idiopathic pulmonary fibrosis, whose lungs were assumed to have DAD pathologically [16–22], lung specimens from patients with ICI-related pneumonitis and radiological DAD pattern on chest HRCT may show similar patterns in BAL analysis. Further studies are needed to clarify the characteristics of BAL analysis in patients with ICI-related pneumonitis and radiologic DAD patterns in chest HRCT, who would die in spite of an appropriate treatment.

The utility of bronchoscopy in obtaining BAL fluid and lung specimens is still undetermined for patients with suspected ICI-related pneumonitis. However, when a differential diagnosis is crucial for other diseases, such as lung infections including pneumocystis pneumonia, lung edema, and pulmonary hemorrhage caused by anticoagulants and/or antiplatelet drugs, evaluation of BAL fluid and/or pathological findings are considered to be useful. When other diagnoses are excluded and ICI-related pneumonitis is most strongly suggested, an increased proportion of lymphocytes may predict a good response to treatment, and a favorable prognosis. Although indications for bronchoscopy should be determined on a case-by-case basis, discussion between the oncologist in charge of the anticancer therapy and the pulmonologist is important.

There are some limitations to this study. First, our study was performed at a single center, and had a relatively small sample size. Second, this was a retrospective study. Ten of the twenty-two patients did not undergo bronchoscopy. In addition, we could not evaluate BAL and/or TBLB in patients with severe ICI-related pneumonitis. Therefore, markers indicating poor treatment response and prognosis were not evaluated. These limitations warrant further prospective studies including more patients undergoing bronchoscopic evaluation. A similar analysis in patients with ICI-related pneumonitis and other types of cancer should also be performed.

Conclusions
The major characteristic of BAL analysis in patients with NSCLC and ICI-related pneumonitis was an increase in the proportion of lymphocytes to >20%. Histologic features of lung tissue obtained by TBLB included alveolitis and/or OP. Acute lung injury and fibrosis were also observed. As all the patients who underwent bronchoscopy demonstrated favorable courses in the study, the increased proportion of lymphocytes in BAL fluid may be an indicator of good treatment response. Although the necessity of bronchoscopy should be determined on a case-by-case basis, it is necessary to assess these parameters discussed in the present study when proper differential diagnosis is needed.

Abbreviations
AIP: Acute interstitial pneumonia; BAL: Bronchoalveolar lavage; DAD: Diffuse alveolar damage; HP: Hypersensitivity pneumonia; HRCT: High-resolution computed tomography; ICI: Immune checkpoint inhibitor; irAE: Immune-related adverse events; mMRC: Modified Medical Research Council; NSCLC: Non-small cell lung cancer; NSIP: Non-specific interstitial pneumonia; OP: Organizing pneumonia; PD-1: Programmed death 1; PD-L1: Programmed death ligand 1; TBLB: Transbronchial lung biopsy.

Authors’ contributions
ON was involved in the conceptualization of the study. All authors were involved in data curation or formal analyses. ON and SS were involved in writing the original draft. All authors contributed to writing, reviewing, and editing the manuscript.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate
Informed consent was waived, because this study was based on a retrospective analysis of case records from our university hospital. Approval for the use of these data and the analysis was provided by the Ethics Committee of the Kindai University Faculty of Medicine (No. 27-001). All methods were performed in accordance with the relevant guidelines and regulations of the Declaration of Helsinki.

Competing interests
HH received funding from Ono Pharmaceutical Co., Ltd. out of this work. KN received funding from Ono Pharmaceutical Co., Ltd. and Merck & Co., Inc. out of this work.

Author details
1 Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, Osaka, Japan. 2 Department of Laboratory Medicine and Pathology, NHO Kinki-Chuo Chest Medical Center, Sakai, Osaka, Japan. 3 Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.

Received: 10 March 2021 Accepted: 30 April 2021
Published online: 08 May 2021

References
1. Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95.
2. Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordana K, Committee EG: Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(4):iv119–iv142.
3. Brahmer JR, Lasserre C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau J, Ernstoff MS, Gardner JM, Ginex P, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–68.
4. Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maatallah JA, Taibi M, Hatabu H, Ott PA, Armand PF, Hodi FS. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051–60.
5. Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):209–17.
6. DeLanaey M, Cadranel J, Lusche A, Meyer N, Gouant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N, Guisier F, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50:2.
7. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607–16.
8. Shao J, Wang C, Ren P, Jiang Y, Tian F, Li W. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer. Biosci Rep. 2020;40:S.
9. Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY, Ryerson CJ, Franquet T, Bankier AA, Brown KK, et al. Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society. Chest. 2021;159(3):1107–25.
10. Meyers KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, Drent M, Haslam PL, Kim DS, Nagai S, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185(9):1004–14.
11. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–82.
12. Akamatsu H, Ninomiya K, Kemmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, et al. The Japanese Lung Cancer Society guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol. 2019;24(7):731–70.
13. Larsen BT, Chae JM, Dixit AS, Hartman TE, Peikert T, Roden AC. Clinical and histopathologic features of immune checkpoint inhibitor-related pneumonitis. Am J Surg Pathol. 2019;43(10):1331–40.
14. Mukhopadhyay S. Predominantly interstitial lung disease. In: Non-neoplastic pulmonary pathology. Cambridge University Press; 2000. p. 185–256.
15. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AL, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.
16. Bonaccorsi A, Cancellieri A, Chilosi M, Trisolini R, Boaron M, Crimi N, Poletti V. Acute interstitial pneumonia: report of a series. Eur Respir J. 2003;21(1):187–91.
17. Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing lung biopsy. Chest. 2005;128(5):3310–5.
18. Ambrosini V, Cancellieri A, Chilosi M, Zompatori M, Trisolini R, Saragoni L, Poletti V. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J. 2003;22(3):821–6.
19. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006;27(1):143–50.
20. Kindoh Y, Taniguchi H, Katsuta T, Kataoka K, Kimura T, Nishiyama O, Sakamoto K, Johkoh T, Nishimura M, Ono K, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(2):103–10.
21. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37(2):356–63.
22. Kataoka K, Taniguchi H, Kindoh Y, Nishiyama O, Kimura T, Matsuda T, Yokoyama T, Sakamoto K, Ando M. Recombinant human thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2015;148(2):436–43.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.